Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing

Area of Science:

• Oncology
• Genomics
• Immunology

Background:

• Multiple myeloma (MM) is a complex plasma cell cancer with current prognostic models having limitations.
• Existing models struggle to fully capture the wide range of patient outcomes in MM.

Purpose of the Study:

• To develop and validate a novel plasma cell gene signature, termed the plasma cell malignancy (PBM) score.
• To assess the PBM score's association with disease state, progression, and clinical outcomes in multiple myeloma.

Main Methods:

• Utilized single-cell RNA-sequencing data to create the PBM gene signature.
• Validated the PBM score across five independent studies, including 2115 samples (1978 MM patients).
• Analyzed associations with disease stage, overall survival, cytogenetic abnormalities, TP53 mutations, and the tumor immune microenvironment.

Main Results:

• A higher PBM score significantly correlated with more advanced plasma cell dyscrasia stages (p < 0.05).
• Elevated PBM scores were linked to shorter overall survival in MM patients (HR = 1.72, p < 0.001).
• The PBM score's prognostic value was independent of the International Staging System (ISS) and Revised ISS (R-ISS).
• Higher PBM scores associated with adverse genetic factors and altered immune microenvironment composition.

Conclusions:

• The PBM score offers a promising new method for refining risk stratification in multiple myeloma.
• This score may aid in guiding therapeutic strategies and clinical decision-making for MM patients.
• The findings highlight the potential of gene expression profiling for improving MM prognostication.